🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join Drs. Komal Jhaveri (Komal Jhaveri), Javier Cortes (Javier Cortes MD PhD) & Sara A. Hurvitz on 5/30 at 6:30 PM CDT, during #ASCO25 for an HR+ #BreastCancer #MedEd event. Produced with Living Beyond Breast Cancer. bit.ly/HRBreast-T #Oncology

Great news! Looking forward to the data ADC sequencing becoming more important a question!

#ASCO25 bringing some key updates in HR+, HER2- #BreastCancer eg, TRADE study, INAVO120, & more). Honored by the opportunity to hear from Drs Komal Jhaveri Sara Hurvitz & Javier Cortes MD PhD this evening (Fri 6:30pm Hilton Chicago)! PeerView Living Beyond Breast Cancer #CME

Coming up at #ASCO25, Komal Jhaveri is chairing a session on current treatment strategies for hormone receptor-positive metastatic #breastcancer. Memorial Sloan Kettering Cancer Center ASCO Learn more: bit.ly/43TFI2c

Whether you are attending ASCO in person or virtually, join us for the educational session - “After a CDK4/6 inhibitor: State of theArt in HR+ MBC “today at 4.30 PM on Hall D2 - Seth Wander, Ricki Fairley, Rena Callahan Memorial Sloan Kettering Cancer Center OncoAlert #bcsm #ASCO2025

Excellent summary of emerging agents for second line therapy and beyond for HR+/HER2- breast cancer by Komal Jhaveri! #ASCO25

📌 After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer 🔛 👉🏻What's on the Horizon: Emerging Agents for Second Line and Beyond in Hormone Receptor-Positive Disease❗️ Komal Jhaveri 👏🏻 #ASCO25 OncoAlert #OncoAlertAF

We still have significant work ahead in developing therapies that deliver meaningful survival gains in breast cancer. But with this regimen demonstrating OS benefit we’re one step closer to changing the standard of care. Toxicity management is key Memorial Sloan Kettering Cancer Center MSK Department of Medicine

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer NEJM OncoAlert ASCO #ASCO25 This is very exciting for our patients !! Komal Jhaveri ! nejm.org/doi/full/10.10…

🚨 A phase 3 clinical trial presented at ASCO has shown that a new three-drug combination enables ER+, HER2 #breastcancer patients to live longer. In the trial, patients receiving the “triplet” therapy had a median survival 26% longer than patients who received the standard

See you tonight (Saturday, May 31st) at Marriott Marquis! Let’s talk through what’s practice changing at #ASCO25 with Hope Rugo Komal Jhaveri Narjust Florez, MD, FASCO Sandip Patel MD FASCO Namrata (Neena) Vijayvergia MD Tanios Bekaii-Saab, MD Enrique Grande Petros Grivas #OncTwitter

Updates from #ASCO25: Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced #breastcancer. Both studies, co-authored by

Komal Jhaveri ASCO Memorial Sloan Kettering Cancer Center OncoAlert It was an amazing discussion

Congrats to Komal Jhaveri, Nicholas Turner of The Breast Cancer Research Foundation, & the team on their NEJM study of overall survival results of inavolisib for PIK3CA-mutated #breastcancer. Dr. Turner will share more at 2:07 p.m. CT at #ASCO25. Memorial Sloan Kettering Cancer Center Read the study: bit.ly/43xNnn3

Kicking off the Oncology Brothers Advancements in Oncology: Breast Cancer ASCO with Hope Rugo and Komal Jhaveri #ASCO25 Hem-Onc Fellows Network

Poster session is starting now at #ASCO25: Fellow Jimmitti Teysir will present a retrospective analysis of treatment patterns in HR+/HER2- metastatic #breastcancer with co-occurring PIK3CA and ESR1 mutations. Memorial Sloan Kettering Cancer Center Komal Jhaveri Learn more: bit.ly/43Ddg3q

OncoAlert Emre Yekedüz Oncology Brothers Dra. María Natalia Gandur Quiroga Cristiane D Bergerot Tom Powles Petros Grivas Sumanta K. Pal, MD, FASCO Enrique Grande Bárbara Melão, MD, PhD Neeraj Agarwal, MD, FASCO gilberto lopes Toni Choueiri, MD Tian Zhang, MD, MHS LARVOL Vivek Subbiah, MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nazli Dizman Dr Joseph McCollom DO Santhosh Ambika UroToday.com

Useful slide to explain clinical outcomes for pts with 1st line, 2nd line and Beyond For HR+ /Her2 -ve MBC . Money 💰 slide by Komal Jhaveri @asco #asco25 OncoAlert Oncology Brothers

On the heels of practice-changing #DB-09 & #ASCENT-04 at #ASC025, pleased to share new review on the role of #ADCs in #brainmets, increasingly key survival determinant in pts w met cancers link.springer.com/article/10.100… #bcsm #lcsm #oncoalert Neurosurgery at Memorial Sloan Kettering MSK Department of Medicine Memorial Sloan Kettering Radiation Oncology

Congratulations Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸